169750-00-9

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 169749-99-9 (3S)-(-)-1-benzyl-3-(methylamino)pyrrolidine 

Downstream Products

• 169750-01-0 (S)-3-[N-(tert-butoxycarbonyl)-N-methylamino]pyrrolidine 
• 764722-45-4 3-(tert-butoxycarbonyl-methyl-amino)-pyrrolidine-1-carboxylic acid 4-nitro-phenyl ester 
• 764719-46-2 5-(4-Ethyl-phenyl)-thiophene-2-carboxylic acid [(S)-1-((R)-3-amino-pyrrolidine-1-carbonyl)-pyrrolidin-3-yl]-methyl-amide 
• 764721-69-9 5-(4-Ethyl-phenyl)-thiophene-2-carboxylic acid methyl-[(S)-1-((R)-3-methylamino-pyrrolidine-1-carbonyl)-pyrrolidin-3-yl]-amide 
• 764719-48-4 5-(4-Methoxy-2-methyl-phenyl)-thiophene-2-carboxylic acid [(S)-1-((R)-3-amino-pyrrolidine-1-carbonyl)-pyrrolidin-3-yl]-methyl-amide 
• 764722-68-1 5-(4-Trifluoromethyl-phenyl)-thiophene-2-carboxylic acid [(S)-1-((R)-3-amino-pyrrolidine-1-carbonyl)-pyrrolidin-3-yl]-methyl-amide 
• 911398-53-3 5-Bromo-thiophene-2-carboxylic acid {(S)-1-[(R)-3-(4,4-dimethyl-cyclohexylamino)-pyrrolidine-1-carbonyl]-pyrrolidin-3-yl}-methyl-amide 
• 917353-86-7 4'-Ethyl-biphenyl-4-carboxylic acid methyl-{(S)-1-[(R)-3-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carbonyl]-pyrrolidin-3-yl}-amide 
• 917358-16-8 5-(4-Ethyl-phenyl)-thiophene-2-carboxylic acid methyl-((S)-1-{(R)-3-[methyl-(2,2,2-trifluoro-acetyl)-amino]-pyrrolidine-1-carbonyl}-pyrrolidin-3-yl)-amide 
• 917354-59-7 5-(4-Ethyl-phenyl)-thiophene-2-carboxylic acid methyl-{(S)-1-[(R)-3-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carbonyl]-pyrrolidin-3-yl}-amide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2

The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compounds from this series exhibited considerable binding affinity (Ki = 1 nM) and functional activity at MCH-R1, acceptable CYP2D6 inhibition, and good rat brain exposure.

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, Het, X and Cyc are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, X, R1, R2, R3, R4, and R5 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Quinolizinone type compounds

Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.